Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board (IRB) approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with the company anticipating IRB approval at two additional sites during the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation. This development matters because it marks a critical expansion of a trial targeting a specific genetic subset of non-small cell lung cancer patients who often develop resistance to standard treatments.
Part 2 of the HARMONIC trial will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor (TKI) treatment. The amended protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This extended treatment duration could potentially deepen or prolong responses in a patient population with limited options after TKI failure. Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the numerical difference suggests a possible benefit from completing the full six-cycle regimen, supporting the rationale for extending to eight cycles.
The Taiwan approvals are strategically important because they broaden the geographic reach of the trial, potentially accelerating patient enrollment and diversifying the patient pool. Taiwan has a high incidence of EGFR-mutated lung cancer, making it a valuable region for studying therapies targeting this mutation. The ability to enroll patients in Taiwan alongside U.S. sites could speed up data collection and bring LP-300 closer to regulatory submission. For investors, this progress signals execution on Lantern's AI-driven development strategy, which uses its RADR platform to identify patients most likely to benefit from its therapies. To view the full press release, visit https://ibn.fm/CqeDR.
Lantern Pharma leverages its proprietary RADR artificial intelligence and machine-learning platform to transform the cost, pace, and precision of oncology drug development. The platform integrates large-scale genomic and biological data to guide biomarker-driven clinical development. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform provides access to a vast network of wire solutions via InvestorWire to reach diverse target markets, along with article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire and IBN. The full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
